Ulvatne Hilde
Department Medical Microbiology, University Hospital of North Norway, Tromsø, Norway.
Am J Clin Dermatol. 2003;4(9):591-5. doi: 10.2165/00128071-200304090-00001.
Antimicrobial peptides are part of the natural defense against infections in all phyla, including humans. Antimicrobial peptides are considered to be promising alternatives to conventional antimicrobials. Antimicrobial peptides are active against a wide spectrum of pathogens, including multidrug-resistant bacteria, fungi, viruses and parasites. Thus, they are promising candidates for treatment of various skin infections, also infections caused by bacteria such as methicillin resistant Staphylococcus aureus and vancomycin resistant enterococci. However, there are some obstacles, e.g. low tissue penetrability, high production costs, and unknown cytotoxicity, to overcome before antimicrobial peptides will be readily available for the treatment of infectious diseases. Topical administration may solve some of these problems. Some antimicrobial peptides are currently in clinical trials, including peptides developed for treatment of skin infections.
抗菌肽是包括人类在内的所有生物抵御感染的天然防御机制的一部分。抗菌肽被认为是传统抗菌药物的有前途的替代品。抗菌肽对多种病原体具有活性，包括耐多药细菌、真菌、病毒和寄生虫。因此，它们是治疗各种皮肤感染的有前途的候选药物，也可用于治疗由诸如耐甲氧西林金黄色葡萄球菌和耐万古霉素肠球菌等细菌引起的感染。然而，在抗菌肽能够轻易用于治疗传染病之前，还存在一些障碍需要克服，例如组织穿透性低、生产成本高以及细胞毒性未知。局部给药可能会解决其中一些问题。目前一些抗菌肽正在进行临床试验，包括用于治疗皮肤感染的肽。
